HIV integrase inhibitors

Abstract

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

##STR00001##

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This patent application claims the benefit of U.S. provisional patent application No. 61/421,919 filed Dec. 10, 2010.

BACKGROUND OF THE INVENTION

The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

Human immunodeficiency virus (HIV) has been identified as the etiological agent responsible for acquired immune deficiency syndrome (AIDS), a fatal disease characterized by destruction of the immune system and the inability to fight off life threatening opportunistic infections. Recent statistics (UNAIDS: Report on the Global HIV/AIDS Epidemic, December 1998), indicate that as many as 33 million people worldwide are infected with the virus. In addition to the large number of individuals already infected, the virus continues to spread. Estimates from 1998 point to close to 6 million new infections in that year alone. In the same year there were approximately 2.5 million deaths associated with HIV and AIDS.

There are currently a number of antiviral drugs available to combat the infection. These drugs can be divided into four classes based on the viral protein they target and their mode of action. In particular, saquinavir, indinavir, ritonavir, nelfinavir atazanavir darunavir, amprenavir, fosamprenavir, lopinavir and tipranavir are competitive inhibitors of the aspartyl protease expressed by HIV. Zidovudine, didanosine, stavudine, lamivudine, zalcitabine, emtricitibine, tenofovir and abacavir are nucleoside reverse transcriptase inhibitors that behave as substrate mimics to halt viral cDNA synthesis. The non-nucleoside reverse transcriptase inhibitors, nevirapine, delavirdine, efavirenz and etravirine inhibit the synthesis of viral cDNA via a non-competitive (or uncompetitive) mechanism. Enfuvirtide and maraviroc inhibit the entry of the virus into the host cell. Used alone these drugs are effective in reducing viral replication. There are also peptidomimetic protease inhibitors including saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, lopinavir, darunavir, atazanavir, and tipranavir, and integrase inhibitors such as raltegravir. The effect is only temporary as the virus readily develops resistance to all known agents. However, combination therapy has proven very effective at both reducing virus and suppressing the emergence of resistance in a number of patients. In the US, where combination therapy is widely available, the number of HIV-related deaths has declined (Palella, F. J.; Delany, K. M.; Moorman, A. C.; Loveless, M. O.; Further, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D. N Engl. J. Med. 1998, 338, 853-860).

Unfortunately, not all patients are responsive and a large number fail this therapy. In fact, approximately 30-50% of patients ultimately fail combination therapy. Treatment failure in most cases is caused by the emergence of viral resistance. Viral resistance in turn is caused by the rapid turnover of HIV-1 during the course of infection combined with a high viral mutation rate. Under these circumstances incomplete viral suppression caused by insufficient drug potency, poor compliance to the complicated drug regiment as well as intrinsic pharmacological barriers to exposure provides fertile ground for resistance to emerge. More disturbing are recent findings which suggest that low-level replication continues even when viral plasma levels have dropped below detectable levels (<50 copies/ml) (Carpenter, C. C.; Cooper, D. A.; Fischl, M. A.; Gatell, J. M.; Gazzard, B. G.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schechter, M.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; Volberding, P. A. JAMA 2000, 283, 381-390). Clearly, there is a need for new antiviral agents, preferably targeting other viral enzymes to reduce the rate of resistance and suppress viral replication even further.

HIV expresses three enzymes, reverse transcriptase, an aspartyl protease, and integrase. All three are targets for treating AIDS and HIV infection. HIV integrase is a component of the pre-integration complex of the virus that is assembled in the cell shortly after infection (Chiu, T. K.; Davies, D. R. Curr. Top. Med. Chem. 2004, 4, 965-977). This enzyme catalyzes the integration of proviral DNA into the host genome and is absolutely required for viral infectivity. Early experiments showed that mutating the active site of integrase within a proviral clone produces virus unable to replicate due to its inability to insert into the host chromosome (Englund, G.; Theodore, T. S.; Freed, E. O.; Engleman, A.; Martin, M. A. J. Virol. 1995, 69, 3216-3219). Selective HIV integrase inhibitors have been shown to possess effective anti-HIV activity in cell culture (Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Science, 2000, 287, 646-650), and it is clear that this class of inhibitors is very effective as part of a combination regimen containing HIV inhibitors of different classes. An HIV integrase inhibitor, raltegravir (Isentress®), has been approved for use in treatment experienced patients based upon 48 week trial results (Cooper, D. A.; Gatell, J.; Rockstroh, J.; Katlama, C.; Yeni, P.; Lazzarin, A.; Xu, X.; Isaacs, R.; Teppler, H.; Nguyen, B. Y. 15th Conference on Retroviruses and Opportunistic Infections, Boston, Mass., Feb. 3-6, 2008 Abst. 105LB: Evering, T. H.; Markowitz, M. Drugs Today, 2007, 43, 865-877). In addition, a second integrase inhibitor, elvitegravir (GS-9137), completed a successful Phase II trial in combination with ritonavir boosting in naive and treatment experienced patients (Zolopa, A. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, Calif. Feb. 25-28, 2007 Abst. 143LB). Thus, HIV-1 integrase is a promising target for novel anti-HIV-1 therapeutics.

HIV integrase inhibitors have been disclosed. See, for example, PCT patent application publications WO05/061501 and WO2010/088167.

The invention provides technical advantages, for example, the compounds are novel and inhibit HIV integrase. Additionally, the compounds provide advantages for pharmaceutical uses, for example, with regard to one or more of their mechanism of action, binding, inhibition efficacy, target selectivity, solubility, safety profiles, or bioavailability.

DESCRIPTION OF THE INVENTION

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.

One aspect of the invention are compounds of Formula I

##STR00002##
where:
R¹ is hydrogen, alkyl, alkylCO, (tetrahydropyranyl)CO, ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, CO₂R⁴, CON(R⁵)(R⁶), COCO₂R⁴, or COCON(R⁵)(R⁶);
R² is hydrogen or alkyl;
R³ is hydrogen;
R⁴ is hydrogen, alkyl, or benzyl;
R⁵ is hydrogen, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or alkylCO;
R⁶ is hydrogen, alkyl, cycloalkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, or alkylCO;
or N(R⁵)(R⁶) taken together is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, or morpholinyl, and is substituted with 0-3 substituents selected from halo and alkyl;
Ar¹ is tetrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, furanyl, thienyl, or pyrrolyl; Ar¹ is substituted with 1 benzyl moiety which is further substituted with 0-3 substituents selected from halo and alkyl; and Ar¹ is substituted with 0-2 alkyl substituents; and
Ar² is tetrazolyl, triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrrolyl, furanyl, thienyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, or hydroxypyridinyl, and is substituted with 0-3 substituents selected from the group consisting of oxo, halo, cyano, benzyl, alkyl, alkoxy, N(R⁵)(R⁶), CO₂R⁴, and CON(R⁵)(R⁶);
or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of formula I where

R¹ is hydrogen, ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶);

R² is hydrogen or alkyl;

R³ is hydrogen;

R⁵ is hydrogen, alkyl, or alkylCO;

R⁶ is hydrogen or alkyl;

or N(R⁵)(R⁶) taken together is pyrrolidinyl;

Ar¹ is triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or thiazolyl; Ar¹ is substituted with 1 benzyl moiety which is further substituted with 1 halo substituent; and

Ar² is triazolyl, pyrazolyl, isoxazolyl, pyridinyl, or pyridazinyl, and is substituted with 0-1 alkyl substituents;

or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of formula I where R¹ is hydrogen, ((Ar²)(dimethyl)methyl)CO, ((Ar²)cyclopropyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶); R² is hydrogen or methyl; R³ is hydrogen; R⁵ is methyl or acetyl; R⁶ is methyl; or N(R⁵)(R⁶) taken together is pyrrolidinyl; Ar¹ is triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or thiazolyl; Ar¹ is substituted with 1 p-fluorobenzyl; and Ar² is triazolyl, methylpyrazolyl, methylisoxazolyl, pyridinyl, or pyridazinyl; or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a compound of formula I where R¹ is ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶).

Another aspect of the invention is a compound of formula I where R¹ is ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶).

Another aspect of the invention is a compound of formula I where R¹ is COCON(R⁵)(R⁶).

Another aspect of the invention is a compound of formula I where R¹ is COCONMe₂.

Another aspect of the invention is a compound of formula I where Ar¹ is triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or thiazolyl, and Ar¹ is substituted with 1 benzyl moiety which is further substituted with 0-3 substituents selected from halo and alkyl.

Another aspect of the invention is a compound of formula I where Ar² is pyrazolyl or isoxazolyl, and is substituted with 0-1 alkyl substituents.

For a compound of Formula I, the scope of any instance of a variable substituent, including R¹, R², R³, R⁴, R⁵, R⁶, Ar¹, and Ar², can be used independently with the scope of any other instance of a variable substituent. As such, the invention includes combinations of the different aspects.

Unless specified otherwise, these terms have the following meanings. “Halo” means fluoro, chloro, bromo, or iodo. “Alkyl” means a straight or branched alkyl group composed of 1 to 6 carbons. “Alkenyl” means a straight or branched alkyl group composed of 2 to 6 carbons with at least one double bond. “Cycloalkyl” means a monocyclic ring system composed of 3 to 7 carbons. “Hydroxyalkyl,” “alkoxy” and other terms with a substituted alkyl moiety include straight and branched isomers composed of 1 to 6 carbon atoms for the alkyl moiety. “Halo” includes all halogenated isomers from monohalo substituted to perhalo substituted in substituents defined with halo, for example, “Haloalkyl” and “haloalkoxy”, “halophenyl”, “halophenoxy.” “Aryl” means a monocyclic or bicyclic aromatic hydrocarbon groups having 6 to 12 carbon atoms, or a bicyclic fused ring system wherein one or both of the rings is a phenyl group. Bicyclic fused ring systems consist of a phenyl group fused to a four- to six-membered aromatic or non-aromatic carbocyclic ring. Representative examples of aryl groups include, but are not limited to, indanyl, indenyl, naphthyl, phenyl, and tetrahydronaphthyl. “Heteroaryl” means a 5 to 7 membered monocyclic or 8 to 11 membered bicyclic aromatic ring system with 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R. Substituents which are illustrated by chemical drawing to bond at variable positions on a multiple ring system (for example a bicyclic ring system) are intended to bond to the ring where they are drawn to append. For example, substituents R¹ and R² of formula IV are intended to bond to the benzene ring of formula IV and not to the thiophene ring.

“Dioxothiazinyl” means

##STR00003##

The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

Some of the compounds of the invention exist in stereoisomeric forms. The invention includes all stereoisomeric forms of the compounds including enantiomers and diastereromers. Methods of making and separating stereoisomers are known in the art. The invention includes all tautomeric forms of the compounds. An example of a tautomeric pair is shown below.

##STR00004##

The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include ¹³C and ¹⁴C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

Synthetic Methods

The compounds may be made by methods known in the art including those described below and including variations within the skill of the art. Some reagents and intermediates are known in the art. Other reagents and intermediates can be made by methods known in the art using readily available materials. The variables (e.g. numbered “R” substituents) used to describe the synthesis of the compounds are intended only to illustrate how to make the compounds and are not to be confused with variables used in the claims or in other sections of the specification. The following methods are for illustrative purposes and are not intended to limit the scope of the invention.

Abbreviations used in the schemes generally follow conventions used in the art. Chemical abbreviations used in the specification and examples are defined as follows: “NaHMDS” for sodium bis(trimethylsilyl)amide; “DMF” for N,N-dimethylformamide; “MeOH” for methanol; “NBS” for N-bromosuccinimide; “Ar” for aryl; “TFA” for trifluoroacetic acid; “LAH” for lithium aluminum hydride; “BOC”, “DMSO” for dimethylsulfoxide; “h” for hours; “rt” for room temperature or retention time (context will dictate); “min” for minutes; “EtOAc” for ethyl acetate; “THF” for tetrahydrofuran; “EDTA” for ethylenediaminetetraacetic acid; “Et₂O” for diethyl ether; “DMAP” for 4-dimethylaminopyridine; “DCE” for 1,2-dichloroethane; “ACN” for acetonitrile; “DME” for 1,2-dimethoxyethane; “HOBt” for 1-hydroxybenzotriazole hydrate; “DIEA” for diisopropylethylamine, “Nf” for CF₃(CF₂)₃SO₂—; and “TMOF” for trimethylorthoformate.

##STR00005##

##STR00006##

##STR00007##

##STR00008##

Biological Methods

HIV-Integrase Inhibition Activity.

Radiolabeled integrase inhibitor, BMS-641493 was used as a known reference ligand to determine the binding constants towards the integrase enzyme of the compounds described in this invention using a method similar to that described in; Dicker et al. J. Biological Chem. 2007, 282, 31186-31196; Dicker et al. J. Biol. Chem. 2008, 283, 23599-23609 and Dicker et al. Biochemistry 2008, 47, 13481-13488. BMS-641493 is a known active-site binding inhibitor as it can be competed off the Kd values for [3H]BMS-641493 were determined from fitting data to a saturation binding curve using Graphpad Prism, V4.01. The Ki measurement toward integrase was made by measuring the inhibition of binding of [3H]BMS-641493 to enzyme-SPA bead complexes in the presence of serial dilutions of the test compounds. The Ki value was determined from the [3H]BMS-641493 Kd and the inhibition binding curve using Graphpad Prism, V4.03. Results are shown in the Table 1.

TABLE 1

Example Activity μM


2       0.021
3       0.122
4       0.021
5       3.880
6       0.400
7       0.222
8       0.115
9       1.074
10      0.009
11      0.019
12      0.013
13      0.013
14      0.041
15      0.057
16      1.469
17      0.010
18      0.016

Inhibition of HIV Replication.

A recombinant NL-Rluc virus was constructed in which a section of the nef gene from NL4-3 was replaced with the Renilla Luciferase gene. The NL-RLuc virus was prepared by co-transfection of two plasmids, pNLRLuc and pVSVenv. The pNLRLuc contains the NL-Rluc DNA cloned into pUC18 at the PvuII site, while the pVSVenv contains the gene for VSV G protein linked to an LTR promoter. Transfections were performed at a 1:3 ratio of pNLRLuc to pVSVenv on 293T cells using the LipofectAMINE PLUS kit from Invitrogen (Carlsbad, Calif.) according to manufactures instruction, and the pseudotype virus generated was titered in MT-2 cells.

Susceptibility of viruses to compounds was determined by incubation in the presence of serial dilutions of the compound. The 50% effective concentration (EC_H) was calculated by using the exponential form of the median effect equation where (Fa)=1/[1+(ED₅₀/drug conc.)^m] (Johnson V A, Byington R T. Infectivity Assay. In Techniques in HIV Research. ed. Aldovini A, Walker B D. 71-76. New York: Stockton Press. 1990). the results from at least 2 experiments were used to calculate the EC₅₀ values. Results are shown in the Table 2.

TABLE 2

Example Activity μM


1       0.021
2       0.005
3       0.018
4       0.008
5       0.060
6       0.001
7       0.002
8       0.0004
10      0.006
11      0.024
12      0.008
13      0.002
14      0.007
15      0.053
16      0.021
17      0.005
18      0.005

Pharmaceutical Composition and Methods of Use

The compounds of this invention inhibit HIV integrase. HIV integrase inhibitors belonging to a class of diketo acid compounds prevented viral integration and inhibited HIV-1 replication in cells (Hazuda et al. Science 2000, 287, 646). Recently reltegravir, an HIV integrase inhibitor, has been approved by the FDA for treating AIDS and HIV infection.

Accordingly, another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier.

Another aspect of the invention is the use of a compound of formula I in the manufacture of a medicament for the treatment of AIDS or HIV infection.

Another aspect of the invention is a method for treating HIV infection in a human patient comprising the administration of a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

Another aspect of the invention is a method wherein the agent is a nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is a method wherein the nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a non-nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is a method wherein the non-nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of delavirdine, efavirenz, and nevirapine, or a pharmaceutically acceptable thereof.

Another aspect of the invention is a method wherein the agent is an HIV protease inhibitor.

Another aspect of the invention is a method wherein the HIV protease inhibitor is selected from the group consisting of amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and fosamprenavir, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV fusion inhibitor.

Another aspect of the invention is a method wherein the HIV fusion inhibitor is enfuvirtide or T-1249, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV attachment inhibitor.

Another aspect of the invention is a method wherein the agent is a CCR5 inhibitor.

Another aspect of the invention is a method wherein the CCR5 inhibitor is selected from the group consisting of Sch-C, Sch-D, TAK-220, PRO-140, and UK-427,857, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a CXCR4 inhibitor.

Another aspect of the invention is a method wherein the CXCR4 inhibitor is AMD-3100, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV budding or maturation inhibitor.

Another aspect of the invention is a method wherein the budding or maturation inhibitor is PA-457, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is an HIV integrase inhibitor.

Another aspect of the invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, with at least one other agent used for treatment of AIDS or HIV infection selected from the group consisting of nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier.

Another aspect of the invention is the composition wherein the agent is a nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is the composition wherein the nucleoside HIV transcriptase inhibitor is selected from the group consisting of abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is a non-nucleoside HIV reverse transcriptase inhibitor.

Another aspect of the invention is the composition wherein the non-nucleoside HIV reverse transcriptase inhibitor is selected from the group consisting of delavirdine, efavirenz, and nevirapine, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV protease inhibitor.

Another aspect of the invention is the composition wherein the HIV protease inhibitor is selected from the group consisting of amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and fosamprenavir, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV fusion inhibitor.

Another aspect of the invention is the composition method wherein the HIV fusion inhibitor is enfuvirtide or T-1249, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV attachment inhibitor.

Another aspect of the invention is the composition wherein the agent is a CCR5 inhibitor.

Another aspect of the invention is the composition wherein the CCR5 inhibitor is selected from the group consisting of Sch-C, Sch-D, TAK-220, PRO-140, and UK-427,857, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is a method wherein the agent is a CXCR4 inhibitor.

Another aspect of the invention is a method wherein the CXCR4 inhibitor is AMD-3100 or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV budding or maturation inhibitor.

Another aspect of the invention is the composition wherein the budding or maturation inhibitor is PA-457, or a pharmaceutically acceptable salt thereof.

Another aspect of the invention is the composition wherein the agent is an HIV integrase inhibitor.

“Combination,” “coadministration,” “concurrent,” and similar terms referring to the administration of a compound of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or highly active antiretroviral therapy (HAART) as understood by practitioners in the field of AIDS and HIV infection.

“Therapeutically effective” means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of AIDS and HIV infection. In general, the goals of treatment are suppression of viral load, restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related morbidity and mortality.

“Patient” means a person infected with the HIV virus and suitable for therapy as understood by practitioners in the field of AIDS and HIV infection.

“Treatment,” “therapy,” “regimen,” “HIV infection,” “ARC,” “AIDS” and related terms are used as understood by practitioners in the field of AIDS and HIV infection.

The compounds of this invention are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt and a pharmaceutically acceptable carrier and may contain conventional excipients. A therapeutically effective amount is that which is needed to provide a meaningful patient benefit. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms including capsules, tablets, losenges, and powders as well as liquid suspensions, syrups, elixers, and solutions. Compositions are made using common formulation techniques, and conventional excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) are generally used for compositions. See, for example, Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pa. (1985).

Solid compositions are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 0.25-1000 mg/unit.

Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is 1-100 mg/mL.

The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other antiretroviral agents used clinically. Typically, the daily dose will be 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regime, however, will be determined by a physician using sound medical judgement.

The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating AIDS and HIV infection. Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti-infectives. In these combination methods, the compound of Formula I will generally be given in a daily dose of 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regime, however, will be determined by a physician using sound medical judgement. A partial list of such agents is shown in the table below.

Drug Name	Manufacturer	Indication
ANTIVIRALS
097	Hoechst/Bayer	HIV infection,
		AIDS, ARC
		(non-nucleoside
		reverse trans-
		criptase (RT)
		inhibitor)
Amprenavir	Glaxo Wellcome	HIV infection,
141 W94		AIDS, ARC
GW 141		(protease inhibitor)
Abacavir (1592U89)	Glaxo Wellcome	HIV infection,
GW 1592		AIDS, ARC
		(RT inhibitor)
Acemannan	Carrington Labs	ARC
	(Irving, TX)
Acyclovir	Burroughs Wellcome	HIV infection, AIDS,
		ARC
AD-439	Tanox Biosystems	HIV infection, AIDS,
		ARC
AD-519	Tanox Biosystems	HIV infection, AIDS,
		ARC
Adefovir dipivoxil	Gilead Sciences	HIV infection
AL-721	Ethigen	ARC, PGL
	(Los Angeles, CA)	HIV positive, AIDS
Alpha Interferon	Glaxo Wellcome	Kaposi's sarcoma,
		HIV in combination
		w/Retrovir
Ansamycin	Adria Laboratories	ARC
LM 427	(Dublin, OH)
	Erbamont
	(Stamford, CT)
Antibody which	Advanced Biotherapy	AIDS, ARC
Neutralizes pH	Concepts
Labile alpha aberrant	(Rockville, MD)
Interferon
AR177	Aronex Pharm	HIV infection, AIDS,
		ARC
Beta-fluoro-ddA	Nat'l Cancer Institute	AIDS-associated
		diseases
BMS-234475	Bristol-Myers Squibb/	HIV infection,
(CGP-61755)	Novartis	AIDS, ARC
		(protease inhibitor)
CI-1012	Warner-Lambert	HIV-1 infection
Cidofovir	Gilead Science	CMV retinitis,
		herpes, papillomavirus
Curdlan sulfate	AJI Pharma USA	HIV infection
Cytomegalovirus	MedImmune	CMV retinitis
Immune globin
Cytovene	Syntex	Sight threatening
Ganciclovir		CMV
		peripheral CMV
		retinitis
Darunavir	Tibotec- J & J	HIV infection, AIDS,
		ARC (protease inhibitor)
Delaviridine	Pharmacia-Upjohn	HIV infection,
		AIDS, ARC
		(RT inhibitor)
Dextran Sulfate	Ueno Fine Chem.	AIDS, ARC, HIV
	Ind. Ltd. (Osaka,	positive
	Japan)	asymptomatic
ddC	Hoffman-La Roche	HIV infection, AIDS,
Dideoxycytidine		ARC
ddI	Bristol-Myers Squibb	HIV infection, AIDS,
Dideoxyinosine		ARC; combination
		with AZT/d4T
DMP-450	AVID	HIV infection,
	(Camden, NJ)	AIDS, ARC
		(protease inhibitor)
Efavirenz	Bristol Myers Squibb	HIV infection,
(DMP 266, Sustiva ®)		AIDS, ARC
(-)6-Chloro-4-(S)-		(non-nucleoside RT
cyclopropylethynyl-		inhibitor)
4(S)-trifluoro-
methyl-1,4-dihydro-
2H-3,1-benzoxazin-
2-one, STOCRINE
EL10	Elan Corp, PLC	HIV infection
	(Gainesville, GA)
Etravirine	Tibotec/J & J	HIV infection, AIDS,
		ARC (non-nucleoside
		reverse transcriptase
		inhibitor)
Famciclovir	Smith Kline	herpes zoster,
		herpes simplex
GS 840	Gilead	HIV infection,
		AIDS, ARC
		(reverse transcriptase
		inhibitor)
HBY097	Hoechst Marion	HIV infection,
	Roussel	AIDS, ARC
		(non-nucleoside
		reverse transcriptase
		inhibitor)
Hypericin	VIMRx Pharm.	HIV infection, AIDS,
		ARC
Recombinant Human	Triton Biosciences	AIDS, Kaposi's
Interferon Beta	(Almeda, CA)	sarcoma, ARC
Interferon alfa-n3	Interferon Sciences	ARC, AIDS
Indinavir	Merck	HIV infection, AIDS,
		ARC, asymptomatic
		HIV positive, also in
		combination with
		AZT/ddI/ddC
ISIS 2922	ISIS Pharmaceuticals	CMV retinitis
KNI-272	Nat'l Cancer Institute	HIV-assoc. diseases
Lamivudine, 3TC	Glaxo Wellcome	HIV infection,
		AIDS, ARC
		(reverse
		transcriptase
		inhibitor); also
		with AZT
Lobucavir	Bristol-Myers	CMV infection
	Squibb
Nelfinavir	Agouron	HIV infection,
	Pharmaceuticals	AIDS, ARC
		(protease inhibitor)
Nevirapine	Boeheringer	HIV infection,
	Ingleheim	AIDS, ARC
		(RT inhibitor)
Novapren	Novaferon Labs, Inc.	HIV inhibitor
	(Akron, OH)
Peptide T	Peninsula Labs	AIDS
Octapeptide	(Belmont, CA)
Sequence
Trisodium	Astra Pharm.	CMV retinitis, HIV
Phosphonoformate	Products, Inc.	infection, other CMV
		infections
PNU-140690	Pharmacia Upjohn	HIV infection,
		AIDS, ARC
		(protease inhibitor)
Probucol	Vyrex	HIV infection, AIDS
RBC-CD4	Sheffield Med.	HIV infection,
	Tech (Houston, TX)	AIDS, ARC
Ritonavir	Abbott	HIV infection,
		AIDS, ARC
		(protease inhibitor)
Saquinavir	Hoffmann-	HIV infection,
	LaRoche	AIDS, ARC
		(protease inhibitor)
Stavudine; d4T	Bristol-Myers	HIV infection, AIDS,
Didehydrodeoxy-	Squibb	ARC
Thymidine
Tipranavir	Boehringer	HIV infection, AIDS, ARC
	Ingelheim	(protease inhibitor)
Valaciclovir	Glaxo Wellcome	Genital HSV & CMV
		Infections
Virazole	Viratek/ICN	asymptomatic HIV
Ribavirin	(Costa Mesa, CA)	positive, LAS, ARC
VX-478	Vertex	HIV infection, AIDS,
		ARC
Zalcitabine	Hoffmann-LaRoche	HIV infection, AIDS,
		ARC, with AZT
Zidovudine; AZT	Glaxo Wellcome	HIV infection, AIDS,
		ARC, Kaposi's
		sarcoma, in combination
		with other therapies
Tenofovir disoproxil,	Gilead	HIV infection,
fumarate salt		AIDS,
(Viread ®)		(reverse transcriptase
		inhibitor)
Emtriva ®	Gilead	HIV infection,
(Emtricitabine)		AIDS,
(FTC)		(reverse transcriptase
		inhibitor)
Combivir ®	GSK	HIV infection,
		AIDS,
		(reverse transcriptase
		inhibitor)
Abacavir succinate	GSK	HIV infection,
(or Ziagen ®)		AIDS,
		(reverse transcriptase
		inhibitor)
Reyataz ®	Bristol-Myers	HIV infection
(or atazanavir)	Squibb	AIDs, protease
		inhibitor
Fuzeon ®	Roche/Trimeris	HIV infection
(Enfuvirtide or T-20)		AIDs, viral Fusion
		inhibitor
Lexiva®	GSK/Vertex	HIV infection
(or Fosamprenavir		AIDs, viral protease
calcium)		inhibitor
Selzentry	Pfizer	HIV infection
Maraviroc;		AIDs, (CCR5 antagonist,
(UK 427857)		in development)
Trizivir ®	GSK	HIV infection
		AIDs, (three drug
		combination)
Sch-417690	Schering-Plough	HIV infection
(vicriviroc)		AIDs, (CCR5 antagonist,
		in development)
TAK-652	Takeda	HIV infection
		AIDs, (CCR5 antagonist,
		in development)
GSK 873140	GSK/ONO	HIV infection
(ONO-4128)		AIDs, (CCR5 antagonist,
		in development)
Integrase Inhibitor	Merck	HIV infection
MK-0518		AIDs
Raltegravir
Truvada ®	Gilead	Combination of Tenofovir
		disoproxil fumarate salt
		(Viread ®) and Emtriva ®
		(Emtricitabine)
Integrase Inhibitor	Gilead/Japan	HIV Infection
GS917/JTK-303	Tobacco	AIDs
Elvitegravir		in development
Triple drug	Gilead/Bristol-	Combination of Tenofovir
combination	Myers Squibb	disoproxil fumarate salt
Atripla ®		(Viread ®), Emtriva ®
		(Emtricitabine), and
		Sustiva ® (Efavirenz)
Festinavir ®	Oncolys BioPharma	HIV infection
		AIDs
		in development
CMX-157	Chimerix	HIV infection
Lipid conjugate of		AIDs
nucleotide tenofovir
GSK1349572	GSK	HIV infection
Integrase inhibitor		AIDs
IMMUNOMODULATORS
AS-101	Wyeth-Ayerst	AIDS
Bropirimine	Pharmacia Upjohn	Advanced AIDS
Acemannan	Carrington Labs, Inc.	AIDS, ARC
	(Irving, TX)
CL246,738	Wyeth	AIDS, Kaposi's
	Lederle Labs	sarcoma
FP-21399	Fuki ImmunoPharm	Blocks HIV fusion
		with CD4+ cells
Gamma Interferon	Genentech	ARC, in combination
		w/TNF (tumor
		necrosis factor)
Granulocyte	Genetics Institute	AIDS
Macrophage Colony	Sandoz
Stimulating Factor
Granulocyte	Hoechst-Roussel	AIDS
Macrophage Colony	Immunex
Stimulating Factor
Granulocyte	Schering-Plough	AIDS,
Macrophage Colony		combination
Stimulating Factor		w/AZT
HIV Core Particle	Rorer	Seropositive HIV
Immunostimulant
IL-2	Cetus	AIDS, in combination
Interleukin-2		w/AZT
IL-2	Hoffman-LaRoche	AIDS, ARC, HIV, in
Interleukin-2	Immunex	combination w/AZT
IL-2	Chiron	AIDS, increase in
Interleukin-2		CD4 cell counts
(aldeslukin)
Immune Globulin	Cutter Biological	Pediatric AIDS, in
Intravenous	(Berkeley, CA)	combination w/AZT
(human)
IMREG-1	Imreg	AIDS, Kaposi's
	(New Orleans, LA)	sarcoma, ARC, PGL
IMREG-2	Imreg	AIDS, Kaposi's
	(New Orleans, LA)	sarcoma, ARC, PGL
Imuthiol Diethyl	Merieux Institute	AIDS, ARC
Dithio Carbamate
Alpha-2	Schering Plough	Kaposi's sarcoma
Interferon		w/AZT, AIDS
Methionine-	TNI Pharmaceutical	AIDS, ARC
Enkephalin	(Chicago, IL)
MTP-PE	Ciba-Geigy Corp.	Kaposi's sarcoma
Muramyl-Tripeptide
Granulocyte	Amgen	AIDS, in combination
Colony Stimulating		w/AZT
Factor
Remune	Immune Response	Immunotherapeutic
	Corp.
rCD4	Genentech	AIDS, ARC
Recombinant
Soluble Human CD4
rCD4-IgG		AIDS, ARC
hybrids
Recombinant	Biogen	AIDS, ARC
Soluble Human CD4
Interferon	Hoffman-La Roche	Kaposi's sarcoma
Alfa 2a		AIDS, ARC,
		in combination w/AZT
SK&F106528	Smith Kline	HIV infection
Soluble T4
Thymopentin	Immunobiology	HIV infection
	Research Institute
	(Annandale, NJ)
Tumor Necrosis	Genentech	ARC, in combination
Factor; TNF		w/gamma Interferon
ANTI-INFECTIVES
Clindamycin with	Pharmacia Upjohn	PCP
Primaquine
Fluconazole	Pfizer	Cryptococcal
		meningitis,
		candidiasis
Pastille	Squibb Corp.	Prevention of
Nystatin Pastille		oral candidiasis
Ornidyl	Merrell Dow	PCP
Eflornithine
Pentamidine	LyphoMed	PCP treatment
Isethionate (IM & IV)	(Rosemont, IL)
Trimethoprim		Antibacterial
Trimethoprim/sulfa		Antibacterial
Piritrexim	Burroughs Wellcome	PCP treatment
Pentamidine	Fisons Corporation	PCP prophylaxis
Isethionate for
Inhalation
Spiramycin	Rhone-Poulenc	Cryptosporidial
	diarrhea
Intraconazole-	Janssen-Pharm.	Histoplasmosis;
R51211		cryptococcal
		meningitis
Trimetrexate	Warner-Lambert	PCP
Daunorubicin	NeXstar, Sequus	Kaposi's sarcoma
Recombinant Human	Ortho Pharm. Corp.	Severe anemia
Erythropoietin		assoc. with AZT
		therapy
Recombinant Human	Serono	AIDS-related
Growth Hormone		wasting, cachexia
Megestrol Acetate	Bristol-Myers Squibb	Treatment of
		anorexia assoc.
		W/AIDS
Testosterone	Alza, Smith Kline	AIDS-related wasting
Total Enteral	Norwich Eaton	Diarrhea and
Nutrition	Pharmaceuticals	malabsorption
		related to AIDS

DESCRIPTION OF SPECIFIC EMBODIMENTS

Abbreviations used in the schemes generally follow conventions used in the art. Chemical abbreviations used in the specification and Examples are defined as follows: “NaHMDS” for sodium bis(trimethylsilyl)amide; “DMF” for N,N-dimethylformamide; “MeOH” for methanol; “NBS” for N-bromosuccinimide; “Ar” for aryl; “TFA” for trifluoroacetic acid; “LAH” for lithium aluminum hydride; “BOC”, “DMSO” for dimethylsulfoxide; “h” for hours; “rt” for room temperature or retention time (context will dictate); “min” for minutes; “EtOAc” for ethyl acetate; “THF” for tetrahydrofuran; “EDTA” for ethylenediaminetetraacetic acid; “Et₂O” for diethyl ether; “DMAP” for 4-dimethylaminopyridine; “DCE” for 1,2-dichloroethane; “ACN” for acetonitrile; “DME” for 1,2-dimethoxyethane; “HOBt” for 1-hydroxybenzotriazole hydrate; “DIEA” for diisopropylethylamine, “Nf” for CF₃(CF₂)₃SO₂—; and “TMOF” for trimethylorthoformate.

Abbreviations as used herein, are defined as follows: “1×” for once, “2×” for twice, “3×” for thrice, “° C.” for degrees Celsius, “eq” for equivalent or equivalents, “g” for gram or grams, “mg” for milligram or milligrams, “L” for liter or liters, “mL” for milliliter or milliliters, “μL” for microliter or microliters, “N” for normal, “M” for molar, “mmol” for millimole or millimoles, “min” for minute or minutes, “h” for hour or hours, “rt” for room temperature, “RT” for retention time, “atm” for atmosphere, “psi” for pounds per square inch, “conc.” for concentrate, “sat” or “sat'd” for saturated, “MW” for molecular weight, “mp” for melting point, “cc” for enantiomeric excess, “MS” or “Mass Spec” for mass spectrometry, “ESI” for electrospray ionization mass spectroscopy, “HR” for high resolution, “HRMS” for high resolution mass spectrometry, “LCMS” for liquid chromatography mass spectrometry, “HPLC” for high pressure liquid chromatography, “RP HPLC” for reverse phase HPLC, “TLC” or “tlc” for thin layer chromatography, “NMR” for nuclear magnetic resonance spectroscopy, “¹H” for proton, “δ” for delta, “s” for singlet, “d” for doublet, “t” for triplet, “q” for quartet, “m” for multiplet, “br” for broad, “Hz” for hertz, and “α”, “β”, “R”, “S”, “E”, and “Z” are stereochemical designations familiar to one skilled in the art.

##STR00009##

2-(Diphenylmethyleneamino)-3-(4-fluorophenyl)propanenitrile

(Procedure adapted from J. Org. Chem. 2003, 68, 50-54). To a solution of 2-(diphenylmethyleneamino)acetonitrile (1.21 g, 5.47 mmol, 1.0 equiv) in CH₂Cl₂ (9.12 mL) was added 4-fluorobenzyl bromide (0.75 mL, 6.02 mmol, 1.1 equiv), benzyltrimethylammonium chloride (0.10 g, 0.547 mmol, 0.1 equiv), and NaOH (0.99 mL of a 10 M aqueous solution, 9.85 mmol, 1.8 equiv). The reaction was stirred vigorously for 18 h, at which time TLC analysis indicated complete consumption of the starting nitrile. The reaction was added to water and extracted with CH₂Cl₂ (×3). The combined CH₂Cl₂ extracts were dried (Na₂SO₄) and concentrated in vacuo. The crude product was purified by silica gel chromatography (5-30% ethyl acetate/hexane) to provide the title compound (1.65 g, 92% yield) as a viscous yellow oil. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.54-7.65 (m, 2H), 7.38-7.48 (m, 4H), 7.31-7.38 (m, 2H), 7.00-7.09 (m, 2H), 6.89-6.97 (m, 2H), 6.84 (d, J=6.30 Hz, 2H), 4.35 (dd, J=7.81, 6.04 Hz, 1H), 3.10-3.29 (m, 2H); LCMS (ES+, (M+H)⁺) m/z 329.25.

##STR00010##

2-Amino-3-(4-fluorophenyl)propanenitrile hydrochloride

To a solution of 2-(diphenylmethyleneamino)-3-(4-fluorophenyl)propanenitrile, intermediate 1 (1.65 g, 5.02 mmol, 1.0 equiv) in THF (20.1 mL) was added HCl (5.53 mL of a 1 M aqueous solution, 5.53 mmol, 1.1 equiv). After stirring 3 h, the reaction was poured into water and washed with ether (×3). The aqueous layer was neutralized by the addition of 10 M NaOH and extracted with CH₂Cl₂ (×3). The combined CH₂Cl₂ extracts were dried (Na₂SO₄) and then concentrated in vacuo to provide the title compound (0.77 g, 93% yield) as a colorless oil. For convenience, the amine could be converted into the hydrochloride salt by dissolution in ether, treating with 2 M HCl in ether, and filtering the resulting white solid: ¹H NMR (400 MHz, CDCl₃) δ ppm 7.24-7.29 (m, 2H), 7.01-7.08 (m, 2H), 3.85-3.96 (m, 1H), 2.92-3.07 (m, 2H), 1.60 (d, J=7.55 Hz, 2H).

##STR00011##

Ethyl 3-(benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylate

To a solution of ethyl 10-(((benzyloxy)carbonyl)amino)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylate (prepared according to the procedure in WO2009117540) (500 mg, 1.170 mmol) in DMF (20 mL) was added K₂CO₃ (323 mg, 2.339 mmol) followed by benzyl bromide (0.208 mL, 1.755 mmol) and the resulting mixture was heated at 50° C. for 16 h. After cooling to room temp, water was added and the mixture was extracted with ethyl acetate, dried (Na₂SO₄), filtered and concentrated. The crude product was purified by silica gel chromatography (20-100% ethyl acetate/hexane to afford the title compound (250 mg, 42% yield) as a light yellow liquid. ¹H NMR (500 MHz, CDCl₃) δ: 7.47 (d, 2H, J=7.02 Hz), 7.32-7.39 (m, 8H), 7.19 (brs, 1H), 5.26 (s, 2H), 5.08 (s, 2H), 4.31 (q, 2H, J=7.02 Hz), 4.13 (d, 2H, J=3.97 Hz), 2.87-2.96 (m, 2H), 2.46 (brs, 1H), 1.94-2.03 (m, 2H), 1.80-1.89 (m, 2H), 1.65-1.75 (m, 2H), 1.29 (t, 3H, J=7.32 Hz). LCMS (M+H)=518.28.

##STR00012##

3-(Benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylic acid

To a solution of ethyl 3-(benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylate, Intermediate 3 (250 mg, 0.483 mmol) in EtOH (5 mL) was added water (1.250 mL) followed by LiOH—H₂O (20.27 mg, 0.483 mmol) and the mixture was stirred at room temp for 16 h. Water (10 mL) was then added and the mixture was extracted with ether (100 mL). The aqueous layer was then acidified with 1N HCl and then extracted with ethyl acetate (2×100 mL), washed with brine, dried (Na₂SO₄), filtered and concentrated to afford the title compound (180 mg, 76% yield) as a light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ: 7.51 (d, 2H, J=6.71 Hz), 7.30-7.40 (m, 9H), 5.46 (s, 2H), 5.06 (s, 2H), 4.10-4.15 (m, 2H), 2.47-2.61 (m, 3H), 2.03-2.11 (m, 2H), 1.91-2.01 (m, 2H), 1.63-1.73 (m, 2H). LCMS (M+H)=490.23.

##STR00013##

Benzyl(3-(benzyloxy)-2-((1-cyano-2-(4-fluorophenyl)ethyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of 3-(benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylic acid, Intermediate 4 (180 mg, 0.368 mmol) in CH₂Cl₂ (2 mL) was added oxalyl chloride (0.051 mL, 0.588 mmol) followed by 1 drop of DMF. After stirring for 2 h, the mixture was concentrated under reduced pressure. The crude acid chloride was then diluted with dichloromethane (2 mL) and added to a stirred solution of 2-amino-3-(4-fluorophenyl)propanenitrile HCl (81 mg, 0.404 mmol) and triethylamine (0.205 mL, 1.471 mmol) in CH₂Cl₂ (2 mL) and the resulting solution was stirred at room temperature. After 16 h at room temperature, the reaction mixture was poured into sat. NaHCO₃ and extracted with dichloromethane (50 mL×3), dried (Na₂SO₄), filtered and concentrated to give a yellow oil. The crude product was then purified by silica gel chromatography (50-100% EtOAc/hexane) to afford the title compound (145 mg, 62% yield) as a light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ: 7.82 (brs, 1H), 7.28-7.49 (m, 10H), 7.06-7.17 (m, 2H), 6.96 (t, 2H, J=8.39 Hz), 6.63 (brs, 1H), 5.27-5.40 (m, 2H), 5.00-5.14 (m, 2H), 4.07-4.14 (m, 3H), 2.77-2.92 (m, 2H), 2.64-2.78 (m, 2H), 2.49 (brs, 1H), 1.87-2.02 (m, 4H), 1.63-1.75 (m, 2H). LCMS (M+H)=636.19.

##STR00014##

Benzyl(3-(benzyloxy)-2-(4-chloro-5-(4-fluorobenzyl)-1H-imidazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of benzyl(3-(benzyloxy)-2-((1-cyano-2-(4-fluorophenyl)ethyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 5 (140 mg, 0.220 mmol) in acetonitrile (4 mL) was added carbon tetrachloride (0.053 mL, 0.551 mmol), followed by triphenylphosphine (144 mg, 0.551 mmol) and the mixture was heated at 45° C. After stirring for 16 h, the mixture was cooled to room temp and concentrated in vacuo. The residue was then treated with dichloromethane (10 mL) and 0.5 N NaOH (20 mL). The mixture was then poured into water and extracted with dichloromethane (×4), dried (Na₂SO₄), filtered and concentrated. The crude product was then purified by silica gel chromatography (40-100% EtOAc/hexane) to afford the title compound (90 mg, 42% yield) as a yellow solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 1.65-1.74 (m, 2H) 1.92-2.03 (m, 4H) 2.47 (br. s., 1H) 2.71-2.86 (m, 2H) 3.74 (s, 2H) 4.13 (d, J=3.66 Hz, 2H) 5.12 (s, 2H) 5.29 (s, 2H) 6.92 (d, J=7.63 Hz, 4H) 7.08 (br. s., 1H) 7.29-7.37 (m, 8H) 7.39-7.46 (m, 2H) 10.08 (br. s., 1H). (M+H)=654.28.

##STR00015##

Benzyl(3-(benzyloxy)-2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of 3-(benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylic acid, Intermediate 4 (400 mg, 0.817 mmol) in CH₂Cl₂ (8 mL) was added oxalyl chloride (0.114 mL, 1.307 mmol) followed by 1 drop of DMF. After stirring for 2 h, the mixture was concentrated under reduced pressure. The crude acid chloride was then diluted with dichloromethane (5 mL)) and added to a stirred solution of 1-amino-3-(4-fluorophenyl)propan-2-one HCl (183 mg, 0.899 mmol) and triethylamine (0.456 mL, 3.27 mmol) in CH₂Cl₂ (8.00 mL) and the resulting solution stirred at room temperature. After 16 h the reaction mixture was poured into sat. NaHCO₃ and extracted with dichloromethane (50 mL×3), dried (Na₂SO₄), filtered and concentrated to give a yellow oil. The crude product was then purified by silica gel chromatography (50-100% EtOAc/hexane) to afford the title compound (400 mg, 0.626 mmol, 77% yield) as a light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 7.99 (1H, br. s.), 7.49 (2H, d, J=5.80 Hz), 7.28-7.37 (8H, m), 7.15 (2H, dd, J=8.55, 5.49 Hz), 7.01-7.04 (2H, m), 6.79 (1H, br. s.), 5.32 (2H, s), 5.06 (2H, s), 4.17 (2H, d, J=4.88 Hz), 4.12 (2H, d, J=3.66 Hz), 3.69 (2H, s), 2.67-2.78 (2H, m), 2.47 (1H, br. s.), 1.89-2.01 (4H, m), 1.64-1.72 (2H, m). LCMS (M+H)=640.04.

##STR00016##

Benzyl(3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3-thiazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of benzyl(3-(benzyloxy)-2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 7 (120 mg, 0.188 mmol) in toluene was added Lawesson's Reagent (76 mg, 0.188 mmol) and stirred for 15 min at room temperature, 30 min at 60° C. and 2 h at 100° C. The resulting clear yellow mixture was then cooled, concentrated and purified by preparative HPLC to provide the title compound (60 mg, 0.094 mmol, 50.2% yield) as a yellow solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.79 (1H, s), 7.47-7.52 (2H, m), 7.29-7.39 (8H, m), 7.17 (2H, dd, J=8.28, 5.27 Hz), 6.94-7.07 (3H, m), 5.38 (2H, s), 5.09 (2H, s), 4.09-4.19 (4H, m), 2.69-2.84 (2H, m), 2.49 (1H, br. s.), 1.94-2.04 (4H, m), 1.65-1.76 (2H, m). LCMS (M+H)=637.27.

##STR00017##

Benzyl(3-(benzyloxy)-2-(hydrazinylcarbonyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of 3-(benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylic acid, Intermediate 4 (1 g, 2.043 mmol) in CH₂Cl₂ (20 mL) was added oxalyl chloride (0.286 mL, 3.27 mmol). A few drops of DMF were added and the mixture stirred at room temperature for 2 h. Solvent was then removed under reduced pressure. The crude acid chloride was then diluted with dichloromethane (10 mL)) and added to a stirred solution of hydrazine (0.641 mL, 20.43 mmol) and triethylamine (2.85 mL, 20.43 mmol) in CH₂Cl₂ (20 mL) and the resulting solution stirred at room temperature. After 16 h the reaction mixture was poured into sat. NaHCO₃ and extracted with dichloromethane (50 mL×3), dried (Na₂SO₄), filtered and concentrated to give a yellow oil which was used in the next step without further purification. LCMS (M+H)=504.10.

##STR00018##

Benzyl(3-(benzyloxy)-2-((2-((4-fluorophenyl)acetyl)hydrazinyl)carbonyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of benzyl(3-(benzyloxy)-2-(hydrazinylcarbonyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 9 (400 mg, 0.794 mmol) in CH₂Cl₂ (15 mL) at 0° C. was added triethylamine (0.221 mL, 1.589 mmol) followed by 2-(4-fluorophenyl)acetyl chloride (0.098 mL, 0.715 mmol) and the resulting mixture stirred for 1 h. The mixture was allowed to warm to room temp and stirred for 3 h. The mixture was then concentrated and purified by preparative HPLC to afford the title compound (70 mg, 0.109 mmol, 13.78% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 10.00 (1H, br. s.), 8.35 (1H, br. s.), 7.48-7.53 (2H, m), 7.27-7.38 (10H, m), 7.00-7.07 (2H, m), 6.55 (1H, br. s.), 5.39 (2H, s), 5.05 (2H, s), 4.10 (2H, d, J=3.36 Hz), 3.60 (2H, s), 2.56-2.70 (2H, m), 2.47 (1H, br. s.), 1.88-2.04 (4H, m), 1.59-1.71 (2H, m). LCMS (M+H)=640.35.

##STR00019##

Benzyl(3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a stirred solution of benzyl(3-(benzyloxy)-2-((2-((4-fluorophenyl)acetyl)hydrazinyl)carbonyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 10 (70 mg, 0.109 mmol), Ph₃P (51.7 mg, 0.197 mmol), N,N-diisopropylethylamine (0.115 mL, 0.657 mmol) in acetonitrile (3 mL) was added hexachloroethane (0.016 mL, 0.142 mmol). After 16 h the resulting mixture was purified by preparative HPLC to afford the title compound (30 mg, 0.048 mmol, 44.1% yield) as an off-white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 7.45-7.48 (2H, m), 7.32-7.41 (8H, m), 7.21-7.26 (2H, m), 7.09 (1H, br. s.), 6.95 (2H, t, J=8.55 Hz), 5.40 (2H, s), 5.13 (2H, s), 4.19 (2H, s), 4.18 (2H, d, J=3.66 Hz), 2.87-2.96 (2H, m), 2.52 (1H, br. s.), 1.98-2.08 (2H, m), 1.87-1.95 (2H, m), 1.69-1.78 (2H, m). LCMS (M+H)=622.33.

##STR00020##

10-Amino-2-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-3-hydroxy-7,8,9,10-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one

To a mixture of benzyl(3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 11 (30 mg, 0.048 mmol) in CH₂Cl₂ (2 mL) was added HBr in acetic acid (0.218 mL, 1.206 mmol) and the mixture stirred at room temperature for 16 h. The mixture was concentrated and dried under high vacuum to afford the title compound (18 mg, 0.038 mmol, 78% yield) as a brown solid. ¹H NMR (500 MHz, MeOD) δ ppm 7.39-7.46 (2H, m), 7.08-7.14 (2H, m), 4.38 (2H, s), 4.20 (2H, d, J=3.66 Hz), 2.60 (1H, br. s.), 2.22-2.31 (2H, m), 2.05-2.18 (4H, m), 1.85-1.94 (2H, m). LCMS (M+H)=398.18.

##STR00021##

Benzyl(3-(benzyloxy)-2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate

To a solution of 3-(benzyloxy)-10-(((benzyloxy)carbonyl)amino)-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxylic acid, Intermediate 4 (1 g, 2.043 mmol) in CH₂Cl₂ (20 mL) was added oxalyl chloride (0.286 mL, 3.27 mmol). A few drops of DMF was then added and the mixture stirred at room temperature for 2 h. Solvent was removed under reduced pressure and the crude acid chloride was diluted with dichloromethane (10 mL) and added to a stirred solution of 1-amino-3-(4-fluorophenyl)propan-2-one HCl (0.458 g, 2.247 mmol) and triethylamine (1.139 mL, 8.17 mmol) in CH₂Cl₂ (20 mL). The resulting solution was stirred at room temperature for 16 h then poured into sat. NaHCO₃ and extracted with dichloromethane (50 mL×3), dried (Na₂SO₄), filtered and concentrated to give a yellow oil. The crude product was then purified by silica gel chromatography (50-100% EtOAc/hexane) to afford the title compound (770 mg, 1.206 mmol, 59.0% yield) as a light yellow solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 7.99 (1H, br. s.), 7.49 (2H, d, J=5.80 Hz), 7.28-7.37 (8H, m), 7.15 (2H, dd, J=8.55, 5.49 Hz), 7.01-7.04 (2H, m), 6.79 (1H, br. s.), 5.32 (2H, s), 5.06 (2H, s), 4.17 (2H, d, J=4.88 Hz), 4.12 (2H, d, J=3.66 Hz), 3.69 (2H, s), 2.67-2.78 (2H, m), 2.47 (1H, br. s.), 1.89-2.01 (4H, m), 1.64-1.72 (2H, m). LCMS (M+H)=640.04.

##STR00022##

10-Amino-N-(3-(4-fluorophenyl)-2-oxopropyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxamide

To a mixture of benzyl(3-(benzyloxy)-2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 13 (540 mg, 0.845 mmol) in MeOH (8 mL) was added 1N HCl (0.930 mL, 0.930 mmol) followed by 10% Pd/C (90 mg, 0.085 mmol) and the mixture stirred under a hydrogen atmosphere for 2 h. The mixture was then filtered and thoroughly washed with ethyl acetate. The filtrate was concentrated in vacuo and dried under high vacuum overnight to afford the title compound (318 mg, 0.705 mmol, 83% yield) as an off-white solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 12.07 (1H, br. s.), 9.61 (1H, t, J=5.95 Hz), 7.24-7.30 (2H, m), 7.13-7.20 (2H, m), 4.33 (2H, d, J=6.10 Hz), 4.00 (2H, d, J=3.66 Hz), 3.92 (2H, s), 2.46 (1H, br. s.), 2.01-2.13 (4H, m), 1.79-1.88 (2H, m), 1.68-1.77 (2H, m). LCMS (M+H)=415.15.

##STR00023##

N′-(2-((3-(4-Fluorophenyl)-2-oxopropyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a solution of 10-amino-N-(3-(4-fluorophenyl)-2-oxopropyl)-3-hydroxy-4-oxo-4,6,7,8,9,10-hexahydro-7,10-ethanopyrimido[1,2-a]azepine-2-carboxamide, Intermediate 14 (318 mg, 0.705 mmol) in DMF (8 mL) were added 2-(dimethylamino)-2-oxoacetic acid (165 mg, 1.411 mmol), N,N-diisopropylethylamine (0.739 mL, 4.23 mmol), HATU (536 mg, 1.411 mmol) and DMAP (17.23 mg, 0.141 mmol) and the resulting mixture was stirred at room temperature for 3 h. The mixture was then purified by preparative HPLC to afford the title compound (210 mg, 0.409 mmol, 58.0% yield) as an off-white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 11.67 (1H, br. s.), 8.54 (1H, t, J=5.49 Hz), 8.03 (1H, s), 7.19 (2H, dd, J=8.55, 5.19 Hz), 6.99-7.05 (2H, m), 4.26 (2H, d, J=5.49 Hz), 4.17 (2H, d, J=3.97 Hz), 3.77 (2H, s), 3.28 (3H, s), 2.92 (3H, s), 2.46-2.57 (5H, m), 2.09-2.17 (2H, m), 1.91-2.01 (2H, m), 1.67-1.77 (2H, m). LCMS (M+H)=514.26.

##STR00024##

N′-(3-(Benzyloxy)-2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a mixture of N′-(2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide, Intermediate 15 (140 mg, 0.273 mmol) in DMF (5 mL) was added K₂CO₃ (67.8 mg, 0.491 mmol) followed by (bromomethyl)benzene (0.049 mL, 0.409 mmol) and the resulting mixture stirred at room temp for 16 h. Water was then added and the mixture was extracted with ethyl acetate (2×50 mL), dried (Na₂SO₄), filtered and concentrated. The crude product was purified by silica gel chromatography to afford the title compound (140 mg, 0.162 mmol, 59.5% yield) as a yellow oil. ¹H NMR (500 MHz, CDCl₃) δ ppm 8.73 (1H, s), 8.31 (1H, s), 7.53-7.59 (2H, m), 7.31-7.38 (3H, m), 7.18-7.24 (2H, m), 7.02-7.07 (2H, m), 5.35 (2H, s), 4.73 (2H, s), 4.29 (2H, d, J=5.49 Hz), 4.16 (2H, d, J=3.66 Hz), 2.94 (3H, s), 2.91 (3H, s), 2.70-2.79 (2H, m), 2.53 (1H, br. s.), 1.98-2.12 (4H, m), 1.70-1.80 (2H, m). LCMS (M+H)=604.31.

##STR00025##

N′-(3-(Benzyloxy)-2-(5-(4-fluorobenzyl)-1,3-oxazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a mixture of N′-(3-(benzyloxy)-2-((3-(4-fluorophenyl)-2-oxopropyl)carbamoyl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide, Intermediate 16 (125 mg, 0.207 mmol) in THF (8 mL) was added Burgess Reagent (345 mg, 1.450 mmol) and the mixture heated to reflux for 5 h. The mixture was then cooled, concentrated and purified by preparative HPLC to afford the title compound (65 mg, 0.111 mmol, 53.6% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 9.24 (1H, s), 7.38-7.42 (2H, m), 7.30-7.34 (3H, m), 7.18-7.23 (2H, m), 7.11 (1H, s), 6.99-7.04 (2H, m), 5.38 (2H, s), 4.18 (2H, d, J=3.66 Hz), 4.02 (2H, s), 3.30 (3H, s), 3.03 (3H, s), 2.88-2.96 (2H, m), 2.54 (1H, br. s.), 1.94-2.10 (4H, m), 1.71-1.80 (2H, m). LCMS (M+H)=586.31.

Example 1

##STR00026##

10-Amino-2-[4-[(4-fluorophenyl)methyl]-1H-imidazol-2-yl]-7,8,9,10-tetrahydro-3-hydroxy-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one

To a solution of benzyl(3-(benzyloxy)-2-(4-chloro-5-(4-fluorobenzyl)-1H-imidazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate, Intermediate 6 (60 mg, 0.092 mmol) in MeOH (3 mL) was added formic acid (0.100 mL, 2.65 mmol) followed by 10% Pd/C (98 mg, 0.092 mmol) and the mixture stirred at 40° C. for 3 h. After cooling to room temperature, the mixture was filtered through a pad of celite and concentrated. The mixture was then treated with sat. NaHCO₃, extracted with dichloromethnae (×4), dried (Na₂SO₄), filtered and concentrated to afford the title compound (30 mg, 83% yield) as a light purple solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 1.53-1.60 (m, 2H), 1.73-1.81 (m, 6H), 2.37 (br. s., 1H), 2.51-2.54 (m, 2H), 3.93-3.99 (m, 2H), 4.01 (d, J=3.66 Hz, 2H), 7.10-7.17 (m, 3H), 7.30 (dd, J=8.24, 5.80 Hz, 2H). LCMS (M+H)=396.13.

Example 2

##STR00027##

N′-(2-(4-(4-Fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a stirred solution of 10-amino-2-(4-(4-fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-7,8,9,10-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one, Example 1 (27 mg, 0.068 mmol) and 2-(dimethylamino)-2-oxoacetic acid (11.99 mg, 0.102 mmol) in DMF (3 mL) was added N,N-diisopropylethylamine (0.061 mL, 0.35 mmol), DMAP (1.668 mg, 0.014 mmol) and HATU (38.9 mg, 0.102 mmol) and the resulting mixture stirred at room temp for 3 h. The mixture was then concentrated and purified by preparative HPLC to afford the title compound (6 mg, 8% yield) as an off-white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 1.63-1.77 (m, 2H), 1.93-1.98 (m, 2H), 2.29-2.38 (m, 4H), 2.50 (br. s., 1H), 3.00 (s, 3H), 3.17 (s, 3H), 4.03 (s, 2H), 4.14 (s, 2H), 6.82 (br. s., 1H), 7.00 (t, J=8.39 Hz, 1H), 7.21-7.27 (m, 3H), 7.70 (s, 1H). LCMS (M+H)=495.20.

Example 3

##STR00028##

N-(2-(4-(4-Fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-2-oxo-2-(pyrrolidin-1-yl)acetamide

White solid (20 mg, 38% yield). ¹H NMR (500 MHz, CDCl₃) δ ppm 9.0 (1H, br. s.), 7.1-7.2 (3H, m), 7.0 (3H, t, J=8.55 Hz), 4.1 (4H, br. s.), 3.4-3.6 (3H, m), 2.5 (1H, br. s.), 2.2-2.4 (2H, m), 2.1-2.2 (2H, m), 2.0-2.1 (3H, m), 1.8-1.9 (3H, m), 1.5-1.7 (3H, m). LCMS (M+H)=521.53.

Example 4

##STR00029##

N-(2-(4-(4-Fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-5-methyl-1,2-oxazole-3-carboxamide

To a solution of 10-amino-2-(4-(4-fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-7,8,9,10-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one, Example 1 (30 mg, 0.076 mmol) in CH₂Cl₂ (3 mL) was added triethylamine (0.063 mL, 0.455 mmol) followed by 5-methylisoxazole-3-carbonyl chloride (55.2 mg, 0.379 mmol) and the resulting mixture stirred at room temperature. After 16 h the reaction mixture was concentrated to give the crude product which was treated with 2M dimethylamine/MeOH (0.5 mL) in MeOH (2 mL) at 60° C. for 2 h. The mixture was then cooled and purified by preparative HPLC to afford the title compound (15 mg, 39%) as a white solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 13.4 (1H, br. s.), 9.0 (1H, s), 7.4 (1H, br. s.), 7.4 (2H, dd, J=8.24, 5.80 Hz), 7.2 (2H, t, J=8.85 Hz), 6.6 (1H, s), 4.1 (2H, d, J=3.36 Hz), 4.1 (2H, s), 2.7-2.8 (2H, m), 2.5 (1H, br. s.), 2.0-2.0 (2H, m), 1.9-1.9 (2H, m), 1.7-1.8 (2H, m). LCMS (M+H)=505.49.

Example 5

##STR00030##

10-Amino-3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3-thiazol-2-yl)-7,8,9,10-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one

To a solution of benzyl (3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3-thiazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)carbamate Intermediate 8 (60 mg, 0.094 mmol) in methanol (3 mL) was added 1N HCl (0.104 mL, 0.104 mmol) followed by Pd/C (10.03 mg, 9.42 μmol) and the resulting mixture was stirred under a hydrogen atmosphere for 3 h. The catalyst was removed by filtration and the mixture concentrated then diluted with dichloromethane (3 mL), treated with 48% HBr (0.2 mL) and stirred at room temperature for 16 h. The mixture was concentrated and the crude product was triturated with ethyl acetate/hexane, filtered and dried under high vacuum to afford the title compound HBr salt 0.102 mL, 1.885 mmol) as a dark brown solid. ¹H NMR (500 MHz, DMSO-d₆) δ ppm 7.97 (1H, s), 7.36 (2H, dd, J=8.70, 5.65 Hz), 7.16-7.20 (2H, m), 4.32 (2H, s), 4.05 (2H, d, J=3.36 Hz), 2.46 (1H, br. s.), 2.08-2.16 (2H, m), 1.96-2.04 (2H, m), 1.81-1.89 (2H, m), 1.70-1.79 (2H, m). LCMS (M+H)=414.18.

Example 6

##STR00031##

N′-(2-(5-(4-Fluorobenzyl)-1,3-thiazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a stirred solution of 10-amino-3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3-thiazol-2-yl)-7,8,9,10-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one, Example 5 (35 mg, 0.085 mmol) in DMF (2 mL) was added 2-(dimethylamino)-2-oxoacetic acid (19.87 mg, 0.170 mmol), N,N-diisoproplylethylamine (0.119 mL, 0.679 mmol), HATU (64.5 mg, 0.170 mmol) and DMAP (5.18 mg, 0.042 mmol) and the resulting mixture stirred at room temperature for 16 h. The mixture was purified by preparative HPLC to afford the title compound (7 mg, 0.013 mmol, 15.32% yield) as a light green solid. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.17 (1H, br. s.), 9.04 (1H, br. s.), 7.87 (1H, br. s.), 7.36 (2H, dd, J=8.16, 5.65 Hz), 7.19 (2H, t, J=8.78 Hz), 4.29 (2H, s), 4.06 (2H, d, J=3.51 Hz), 3.04 (3H, s), 2.87 (3H, s), 2.33-2.45 (3H, m), 2.03-2.14 (2H, m), 1.79-1.90 (2H, m), 1.60-1.71 (2H, m). LCMS (M+H)=512.01.

Example 7

##STR00032##

N′-(2-(5-(4-Fluorobenzyl)-1,3,4-oxadiazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a solution of 10-amino-2-(5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl)-3-hydroxy-7,8,9,10-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one, Intermediate 12 (20 mg, 0.042 mmol) in DMF (1.5 mL) was added 2-(dimethylamino)-2-oxoacetic acid (9.79 mg, 0.084 mmol), N,N-dissopropylethylamine (0.044 mL, 0.251 mmol), HATU (31.8 mg, 0.084 mmol) and DMAP (5.11 mg, 0.042 mmol) and the resulting mixture stirred at room temp for 3 h and then purified by preparative HPLC to afford the title compound (5 mg, 9.47 μmol, 22.64% yield) as a purple solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 11.10 (1H, br. s.), 9.60 (1H, s), 7.54 (2H, dd, J=8.39, 5.34 Hz), 7.10 (2H, t, J=8.55 Hz), 4.35 (2H, s), 4.24 (2H, br. s.), 3.44 (3H, s), 3.13 (3H, s), 2.99-3.08 (3H, m), 2.54 (1H, br. s.), 2.03-2.13 (2H, m), 1.85-1.94 (2H, m), 1.72-1.81 (2H, m). LCMS (M+H)+=497.18.

Example 8

##STR00033##

N′-(4-(5-(4-Fluorobenzyl)-1,3-oxazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide

To a solution of N′-(3-(benzyloxy)-2-(5-(4-fluorobenzyl)-1,3-oxazol-2-yl)-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide, Intermediate 17 (60 mg, 0.102 mmol) in CH₂Cl₂ (3 mL) was added TFA (1 mL, 12.98 mmol) and the resulting mixture heated at 40° C. for 16 h. The mixture was concentrated in vacuo and purified by preparative HPLC to afford the title compound (23 mg, 0.046 mmol, 45.3% yield) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm 10.84 (1H, br. s.), 9.74 (1H, s), 7.45 (2H, dd, J=8.55, 5.49 Hz), 7.08 (2H, t, J=8.70 Hz), 6.97 (1H, s), 4.23 (2H, d, J=3.66 Hz), 4.13 (2H, s), 3.43 (3H, s), 3.11 (3H, s), 3.01-3.09 (2H, m), 2.52 (1H, br. s.), 2.02-2.12 (2H, m), 1.84-1.92 (2H, m), 1.72-1.80 (2H, m). LCMS (M+H)=496.28.

Example 9

##STR00034##

N′-[2-[1-[(4-Fluorophenyl)methyl]-1H-1,2,4-triazol-3-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethylethanediamide

¹H NMR (400 MHz, CDCl₃) δ ppm 9.61 (1H, br. s.), 8.25 (1H, br. s.), 7.45 (2H, br. s.), 7.13 (2H, t, J=7.7 Hz), 5.46 (2H, br. s.), 4.22 (2H, br. s.), 3.35 (3H, s), 3.06 (3H, br. s.), 2.97 (2H, br. s.), 2.52 (1H, br. s.), 2.05 (2H, br. s.), 1.94 (2H, br. s.), 1.75 (2H, br. s.); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −111.90 (1F, s); LCMS (ES+, (M+H)⁺) m/z 496.1.

Example 10

##STR00035##

N′-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 7.60 (br. s., 1H), 7.03-7.14 (m, 2H), 6.95 (t, J=8.78 Hz, 1H), 6.87 (s, 1H), 4.15 (d, J=3.01 Hz, 2H), 4.03 (s, 2H), 3.18 (s, 3H), 3.03 (s, 3H), 2.53 (br. s., 1H), 2.37-2.47 (m, 2H), 2.27-2.37 (m, 2H), 2.25 (s, 3H), 1.91-2.04 (m, 2H), 1.73 (br. s., 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.65 (s, 3F), −119.63 (s, 1F); LCMS (ES+, (M+H)⁺) m/z 509.16.

Example 11

##STR00036##

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-3-pyridinecarboxamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 11.42 (br. s., 1H), 9.34 (d, J=3.76 Hz, 1H), 8.39 (d, J=8.03 Hz, 1H), 7.78 (dd, J=8.41, 5.14 Hz, 1H), 7.09-7.19 (m, 2H), 7.08 (s, 1H), 6.96 (t, J=8.91 Hz, 1H), 4.25 (br. s., 2H), 4.17 (br. s., 2H), 3.07-3.27 (m, 2H), 2.56 (br. s., 1H), 2.25 (s, 3H), 2.09-2.21 (m, 2H), 1.92-2.04 (m, 2H), 1.78-1.91 (m, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.40 (s, 3F), −119.20 (s, 1F); LCMS (ES+, (M+H)⁺) m/z 515.1.

Example 12

##STR00037##

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-3-pyridazinecarboxamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 10.95 (br. s., 1H), 9.55 (s, 1H), 8.76 (d, J=7.78 Hz, 1H), 8.66 (d, J=5.52 Hz, 1H), 7.82-7.91 (m, 1H), 6.79-6.97 (m, 3H), 6.44 (s, 1H), 4.17 (br. s., 2H), 3.78 (br. s., 2H), 2.79-2.94 (m, 2H), 2.59 (br. s., 1H), 2.30-2.45 (m, 2H), 2.22 (s, 3H), 1.96-2.10 (m, 2H), 1.69-1.84 (m, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.81 (br. s., 3F), −120.29 (br. s., 1F); LCMS (ES+, (M+H)⁺) m/z 516.0.

Example 13

##STR00038##

N-[2-[4-[(4-Fluorophenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N′,N′-trimethyl-ethanediamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 7.23-7.33 (m, 2H), 6.96-7.07 (m, 3H), 4.10 (s, 2H), 3.69 (br. s., 1H), 3.41 (br. s., 1H), 3.08 (s, 3H), 3.05 (s, 3H), 3.01 (s, 3H), 2.53 (br. s., 1H), 1.99-2.17 (m, 4H), 1.83 (br. s., 2H), 1.60 (br. s., 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.70 (br. s., 3F), −115.73 (br. s., 1F); LCMS (ES+, (M+H)⁺) m/z 509.0.

Example 14

##STR00039##

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-alpha,alpha-dimethyl-1H-1,2,4-triazole-1-acetamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 8.48 (s, 1H), 7.97 (s, 1H), 7.34 (s, 1H), 7.10 (s, 1H), 7.05 (d, J=7.03 Hz, 1H), 6.98-7.03 (m, 1H), 6.95 (t, J=8.78 Hz, 1H), 4.16 (d, J=3.51 Hz, 2H), 4.07 (s, 2H), 2.43-2.55 (m, 3H), 2.24 (d, J=1.51 Hz, 3H), 1.86-1.98 (m, 4H), 1.87 (br. s., 6H), 1.60-1.73 (m, 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.78 (br. s., 3F), −119.54 (s, 1F); LCMS (ES+, (M+H)⁺) m/z 547.2.

Example 15

##STR00040##

1-(Acetylmethylamino)-N-[2-[4-[(4-fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-cyclopropanecarboxamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 8.49 (s, 1H), 7.05-7.14 (m, 2H), 7.02 (s, 1H), 6.94 (q, J=8.55 Hz, 1H), 4.29-4.43 (m, 1H), 3.99-4.20 (m, 3H), 3.00 (s, 3H), 2.41-2.54 (m, 1H), 2.24 (s, 6H), 1.97 (br. s., 4H), 1.77 (br. s., 2H), 1.60 (br. s., 4H), 1.15-1.40 (m, 1H), 0.80-0.92 (m, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −76.28 (br. s., 3F), −120.63 (s, 1F); LCMS (ES+, (M+H)⁺) m/z 549.1.

Example 16

##STR00041##

N′-[2-[5-[(4-Fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethylethanediamide

¹H NMR (400 MHz, CDCl₃) δ ppm 9.40 (1H, s), 7.30-7.38 (2H, m), 7.07 (2H, t, J=8.5 Hz), 4.48 (2H, s), 4.22 (2H, d, J=3.8 Hz), 3.40 (3H, s), 3.05 (3H, s), 2.94 (2H, ddd, J=14.2, 9.4, 5.3 Hz), 2.52 (1H, br. s.), 1.98-2.09 (2H, m), 1.82-1.93 (2H, m), 1.76 (2H, d, J=14.1 Hz); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −114.62 (1F, s); LCMS (ES+, (M+H)⁺) m/z 513.1.

Example 17

##STR00042##

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N′,N′-trimethyl-ethanediamide trifluoroacetate salt

¹H NMR (400 MHz, CDCl₃) δ ppm 6.89-7.17 (m, 4H), 4.07 (s, 2H), 3.66 (br. s., 1H), 3.41 (br. s., 1H), 3.09 (s, 3H), 3.06 (s, 3H), 3.01 (s, 3H), 2.54 (br. s., 1H), 2.25 (s, 3H), 2.09 (br. s., 4H), 1.83 (br. s., 2H), 1.61 (br. s., 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.75 (br. s., 3F), −119.93 (s, 1F); LCMS (ES+, (M+H)⁺) m/z 523.17.

Example 18

##STR00043##

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-1-methyl-1H-pyrazole-3-carboxamide

TFA salt. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.92 (br. s., 1H), 7.40 (d, J=2.01 Hz, 1H), 7.03-7.14 (m, 2H), 6.96 (t, J=8.78 Hz, 1H), 6.76 (d, J=2.26 Hz, 1H), 6.63 (br. s., 1H), 4.03 (br. s., 5H), 3.94 (br. s., 2H), 2.54-2.68 (m, 2H), 2.47-2.54 (m, 1H), 2.27 (br. s., 5H), 2.01 (br. s., 2H), 1.64 (br. s., 2H); ¹⁹F NMR (376 MHz, CDCl₃) δ ppm −75.69 (br. s., 3F), −119.87 (br. s., 1F); LCMS (ES+, (M+H)⁺) m/z 518.1.

It will be evident to one skilled in the art that the present disclosure is not limited to the foregoing illustrative examples, and that it can be embodied in other specific forms without departing from the essential attributes thereof. It is therefore desired that the examples be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

Claims

1. A compound of formula I

2. A compound of claim 1 where:

R¹ is hydrogen, ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶);

R² is hydrogen or alkyl;

R³ is hydrogen;

R⁵ is hydrogen, alkyl, or alkylCO;

R⁶ is hydrogen or alkyl;

or N(R⁵)(R⁶) taken together is pyrrolidinyl;

Ar¹ is triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or thiazolyl; Ar¹ is substituted with 1 benzyl moiety which is further substituted with 1 halo substituent; and

Ar² is triazolyl, pyrazolyl, isoxazolyl, pyridinyl, or pyridazinyl, and is substituted with 0-1 alkyl substituents;

or a pharmaceutically acceptable salt thereof.

3. A compound of claim 2 where

R¹ is hydrogen, ((Ar²)(dimethyl)methyl)CO, ((Ar²)cyclopropyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶); R² is hydrogen or methyl; R³ is hydrogen; R⁵ is methyl or acetyl; R⁶ is methyl; or N(R⁵)(R⁶) taken together is pyrrolidinyl; Ar¹ is triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or thiazolyl; Ar¹ is substituted with 1 p-fluorobenzyl; and Ar² is triazolyl, methylpyrazolyl, methylisoxazolyl, pyridinyl, or pyridazinyl; or a pharmaceutically acceptable salt thereof.

4. A compound of claim 1 where R¹ is ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶).

5. A compound of claim 1 where R¹ is COCON(R⁵)(R⁶).

6. A compound of claim 1 where Ar¹ is triazolyl, oxadiazolyl, thiadiazolyl, imidazolyl, oxazolyl, or thiazolyl, and Ar¹ is substituted with 1 benzyl moiety which is further substituted with 0-3 substituents selected from halo and alkyl.

7. A compound of claim 6 where R¹ is ((Ar²)alkyl)CO, ((Ar²)cycloalkyl)CO, (Ar²)CO, or COCON(R⁵)(R⁶).

8. A compound of claim 7 where Ar² is pyrazolyl or isoxazolyl, and is substituted with 0-1, alkyl substituents.

9. A compound of claim 7 where R¹ is COCON(R⁵)(R⁶).

10. A compound of claim 9 where R¹ is COCONMe₂.

11. A compound of claim 1 selected from the group consisting of

10-Amino-2-[4-[(4-fluorophenyl)methyl]-1H-imidazol-2-yl]-7,8,9,10-tetrahydro-3-hydroxy-7,10-ethanopyrimido[1,2-a]azepin-4(6H)-one;

N′-(2-(4-(4-Fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide;

N-(2-(4-(4-Fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-2-oxo-2-(pyrrolidin-1-yl)acetamide;

N-(2-(4-(4-Fluorobenzyl)-1H-imidazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-5-methyl-1,2-oxazole-3-carboxamide;

N′-(2-(5-(4-Fluorobenzyl)-1,3-thiazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide;

N′-(2-(5-(4-Fluorobenzyl)-1,3,4-oxadiazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide;

N′-(4-(5-(4-Fluorobenzyl)-1,3-oxazol-2-yl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl)-N,N-dimethylethanediamide;

N′-[2-[1-[(4-Fluorophenyl)methyl]-1H-1,2,4-triazol-3-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide;

N′-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide;

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-3-pyridinecarboxamide;

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-3-pyridazinecarboxamide;

N-[2-[4-[(4-Fluorophenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N′,N′-trimethyl-ethanediamide;

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-alpha,alpha-dimethyl-1H-1,2,4-triazole-1-acetamide;

N′-[2-[5-[(4-Fluorophenyl)methyl]-1,3,4-thiadiazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N-dimethyl-ethanediamide;

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-N,N′,N′-trimethyl-ethanediamide; and

N-[2-[4-[(4-Fluoro-3-methylphenyl)methyl]-1H-imidazol-2-yl]-6,7,8,9-tetrahydro-3-hydroxy-4-oxo-7,10-ethanopyrimido[1,2-a]azepin-10(4H)-yl]-1-methyl-1H-pyrazole-3-carboxamide;

or a pharmaceutically acceptable salt thereof.

12. A composition useful for treating HIV infection comprising a therapeutic amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

13. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.